Abstract
Recent advances in designing peptide ligands for therapeutic targets are making peptides an attractive alternative to small molecules and proteins. It is now common to see peptides developed with affinities comparable to antibodies and specificities much better than small molecules or antibodies. This is especially true in the case of tumor targeting cytotoxic drugs or targeted diagnostics where peptides can be used as a delivery vehicle for drugs or diagnostics. Moreover, lessons learned from nature in understanding peptide ligands are proving to be useful in designing better antibodies and small molecule therapeutics.
Keywords: c-MET, HMPs, heterodimer, peptide, VEGFR-2, antibody, small molecule, targeted drugs
Current Pharmaceutical Design
Title: Designer Peptides: Learning from Nature
Volume: 15 Issue: 6
Author(s): A. Shrivastava, A. D. Nunn and M. F. Tweedle
Affiliation:
Keywords: c-MET, HMPs, heterodimer, peptide, VEGFR-2, antibody, small molecule, targeted drugs
Abstract: Recent advances in designing peptide ligands for therapeutic targets are making peptides an attractive alternative to small molecules and proteins. It is now common to see peptides developed with affinities comparable to antibodies and specificities much better than small molecules or antibodies. This is especially true in the case of tumor targeting cytotoxic drugs or targeted diagnostics where peptides can be used as a delivery vehicle for drugs or diagnostics. Moreover, lessons learned from nature in understanding peptide ligands are proving to be useful in designing better antibodies and small molecule therapeutics.
Export Options
About this article
Cite this article as:
Shrivastava A., Nunn D. A. and Tweedle F. M., Designer Peptides: Learning from Nature, Current Pharmaceutical Design 2009; 15(6) . https://dx.doi.org/10.2174/138161209787315620
DOI https://dx.doi.org/10.2174/138161209787315620 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Neurokinin Receptors and Subtypes as Potential Targets in Breast Cancer: Relevance to Bone Marrow Metastasis
Drug Design Reviews - Online (Discontinued) Stromal Cell Derived Factor-1 / CXCL12, CXCR4 and CD26 in the Mobilization and Homing of Hematopoietic Stem and Progenitor Cells
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents IAP Proteins Antagonist: An Introduction and Chemistry of Smac Mimetics under Clinical Development
Current Medicinal Chemistry Potential Use of Vanadium Compounds in Therapeutics
Current Medicinal Chemistry Desensitization Protocol for Rituximab-Induced Serum Sickness
Current Drug Safety Patient-Specific Alpha-Particle Dosimetry
Current Radiopharmaceuticals LncRNA HOTAIR as Prognostic Circulating Marker and Potential Therapeutic Target in Patients with Tumor Diseases
Current Drug Targets Stem Cell Technologies Based on Hemangioblast Technology Focusing on Human Blood Cells
Recent Patents on Drug Delivery & Formulation Proteomic Analysis of Mitochondria in Raji Cells Following Exposure to Radiation: Implications for Radiotherapy Response
Protein & Peptide Letters Respiratory Syncytial Virus (RSV) Prevention and Treatment: Past, Present, and Future
Cardiovascular & Hematological Agents in Medicinal Chemistry An Overview of Notch Signaling in Adult Tissue Renewal and Maintenance
Current Alzheimer Research Cardiotoxicity of Tyrosine-Kinase-Targeting Drugs
Cardiovascular & Hematological Agents in Medicinal Chemistry The Use of Structural Biology in Janus Kinase Targeted Drug Discovery
Current Drug Targets CD26/Dipeptidyl Peptidase IV as a Novel Therapeutic Target for Cancer and Immune Disorders
Mini-Reviews in Medicinal Chemistry Emerging Hsp90 Inhibitors: From Discovery to Clinic
Anti-Cancer Agents in Medicinal Chemistry KSP Inhibitors as Antimitotic Agents
Current Topics in Medicinal Chemistry Doxorubicin vs. ladirubicin: methods for improving osteosarcoma treatment
Mini-Reviews in Medicinal Chemistry Recent Patents Reveal Microtubules as Persistent Promising Target for Novel Drug Development for Cancers
Recent Patents on Anti-Infective Drug Discovery Breast Cancer in the Personal Genomics Era
Current Genomics Heat Shock Protein 90 Inhibitors in Oncology
Current Proteomics